ARTICLE
14 September 2017

FDA Finalizes Guidance for Medical Device Interoperability

DP
Day Pitney LLP

Contributor

Day Pitney LLP logo
Day Pitney LLP is a full-service law firm with more than 300 attorneys in Boston, Connecticut, Florida, New Jersey, New York and Washington, DC. The firm offers clients strong corporate and litigation practices, with experience on behalf of large national and international corporations as well as emerging and middle-market companies. With one of the largest individual clients practices on the East Coast, the firm also has extensive experience assisting individuals and their families, fiduciaries and tax-exempt entities plan for the future.
In final guidance published on September 6, the U. S. Food and Drug Administration (FDA) provided manufacturers with recommendations for ensuring interoperable medical devices are safely and securely designed and developed through a recently published final guidance.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

In final guidance published on September 6, the U. S. Food and Drug Administration (FDA) provided manufacturers with recommendations for ensuring interoperable medical devices are safely and securely designed and developed through a recently published final guidance. The guidance also provides recommendations for labeling an interoperable device and clarity regarding the type of content manufacturers should include in a pre-market submission.

"Interoperability" refers to the ability of two or more products, technologies, or systems to interconnect and use exchanged information such as by displaying, storing, interpreting, or analyzing the shared information. The guidance suggests that the keys to assuring the safety and effectiveness of interoperable medical devices are: (i) designing systems with interoperability as an objective; (ii) conducting verification, validation and risk management; and (iii) specifying the relevant functional, performance, and interface characteristics in a user-friendly manner through labeling.

Manufacturers are advised that when they design and develop devices, they should carefully consider the needs of the anticipated users of the electronic interface (for example, IT personnel or clinician) and the specific purpose of the interoperability. The FDA also recommends that as part of the development process, manufacturers anticipate and address the complex risks associated with interconnectivity in a system of multiple medical devices.

In developing interoperable medical devices, manufacturers should also consider prior FDA guidance aimed at safeguarding against breaches, such as the cybersecurity guidance for medical devices published in December 2016 (discussed here) .


For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.


Click here for more Healthcare Blogs from Day Pitney

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More